TY - JOUR
T1 - Prediction of progression to severe disease in women with late preterm hypertensive disorders of pregnancy
AU - Zwertbroek, Eva
AU - Broekhuijsen, Kim
AU - Langenveld, Josje
AU - van Baaren, Gert-Jan
AU - van den Berg, Paul P.
AU - Bremer, Henk A.
AU - Ganzevoort, Wessel
AU - van Loon, Aren J.
AU - Mol, Ben W. J.
AU - van Pampus, Maria G.
AU - Perquin, Denise A. M.
AU - Rijnders, Robbert J. P.
AU - Scheepers, Hubertina C. J.
AU - Sikkema, Marko J.
AU - Woiski, Mallory D.
AU - Groen, Henk
AU - Franssen, Maureen T. M.
AU - HYPITAT-II Study Grp
PY - 2017/1
Y1 - 2017/1
N2 - IntroductionIf hypertensive disorders of pregnancy are diagnosed before term, the benefits of immediate delivery need to be weighed against the neonatal consequences of preterm delivery. If we are able to predict which women are at high risk of progression to severe disease, they could be targeted for delivery and maternal complications might be reduced. In addition, this may prevent unnecessary preterm births in women at low risk.Material and methodsWe developed a prediction model using data from the HYPITAT-II trail, which evaluated immediate delivery vs. expectant monitoring in women with non-severe hypertensive disorders of pregnancy between 34 and 37weeks of gestation. Univariate and multivariate logistic regression analysis were used to identify relevant variables from clinical and laboratory parameters. The performance of the resulting prediction model was assessed by receiver operating characteristic analysis, calibration and bootstrapping, using the average predicted probabilities.ResultsWe included 519 women, 115 (22.2%) of whom developed severe hypertensive disorders of pregnancy. The prediction model included: maternal age (odds ratio 0.92 per year), gestational age (odds ratio 0.87 per week), systolic blood pressure (odds ratio 1.05 per mmHg), the presence of chronic hypertension (odds ratio 2.4), platelet count (odds ratio 0.996), creatinine (odds ratio 1.02) and lactate dehydrogenase (odds ratio 1.003). The model showed good fit (p=0.64), fair discrimination (area under the curve 0.76, 95% confidence interval 0.73-0.81, p0.45, respectively).ConclusionIn women with non-severe hypertension in pregnancy near term, progression to severe disease can be predicted. This model requires external validation before it can be applied in practice.
AB - IntroductionIf hypertensive disorders of pregnancy are diagnosed before term, the benefits of immediate delivery need to be weighed against the neonatal consequences of preterm delivery. If we are able to predict which women are at high risk of progression to severe disease, they could be targeted for delivery and maternal complications might be reduced. In addition, this may prevent unnecessary preterm births in women at low risk.Material and methodsWe developed a prediction model using data from the HYPITAT-II trail, which evaluated immediate delivery vs. expectant monitoring in women with non-severe hypertensive disorders of pregnancy between 34 and 37weeks of gestation. Univariate and multivariate logistic regression analysis were used to identify relevant variables from clinical and laboratory parameters. The performance of the resulting prediction model was assessed by receiver operating characteristic analysis, calibration and bootstrapping, using the average predicted probabilities.ResultsWe included 519 women, 115 (22.2%) of whom developed severe hypertensive disorders of pregnancy. The prediction model included: maternal age (odds ratio 0.92 per year), gestational age (odds ratio 0.87 per week), systolic blood pressure (odds ratio 1.05 per mmHg), the presence of chronic hypertension (odds ratio 2.4), platelet count (odds ratio 0.996), creatinine (odds ratio 1.02) and lactate dehydrogenase (odds ratio 1.003). The model showed good fit (p=0.64), fair discrimination (area under the curve 0.76, 95% confidence interval 0.73-0.81, p0.45, respectively).ConclusionIn women with non-severe hypertension in pregnancy near term, progression to severe disease can be predicted. This model requires external validation before it can be applied in practice.
KW - Clinical prediction model
KW - preeclampsia
KW - gestational hypertension
KW - chronic hypertension
KW - high-risk pregnancy
KW - SERUM URIC-ACID
KW - MATERNAL COMPLICATIONS
KW - SEVERE PREECLAMPSIA
KW - PERINATAL OUTCOMES
KW - GUIDELINES
KW - MANAGEMENT
KW - ADMISSION
KW - ACCURACY
KW - MODELS
KW - TESTS
U2 - 10.1111/aogs.13051
DO - 10.1111/aogs.13051
M3 - Article
SN - 0001-6349
VL - 96
SP - 96
EP - 105
JO - Acta Obstetricia et Gynecologica Scandinavica
JF - Acta Obstetricia et Gynecologica Scandinavica
IS - 1
ER -